Study of V617F JAK2-positive and JAK2-negative patients within 18 families with myeloproliferative disorders (MPD): Disease characteristics and evolution, EPOR and MPL analysis.

被引：0
|
作者：
Bellanne-Chantelot, Christine
Labopin, Myriam
Bellanger, Florence
Chaumarel, Isabelle
Isnard, Franpoise
Casadevall, Nicole
Vainchenker, William
Thomas, Gilles
Najman, Albert
机构：
[1] Univ Paris 06, Dept Genet, APHP St Antoine, Paris, France
[2] INSERM, U790, IGR, Villejuif, France
[3] Dept Canc Epidemiol & Genet, Gaithersburg, MD USA
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
672
引用
收藏
页码：202A / 202A
页数：1
相关论文
共 50 条
  • [41] Prevalence of the frequency of JAK2 (V617F) mutation in different myeloproliferative disorders in Egyptian patients
    Ebid, Gamal T.
    Ghareeb, Mohamed
    Salaheldin, Omina
    Kamel, Mahmoud M.
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2015, 8 (09): : 11555 - 11559
  • [42] Analysis of JAK2V617F mutation in Chinese patients with myeloproliferative disorders
    Chen, Suning
    Fei, Hairong
    Zhang, Ri
    Xue, Yongquan
    Pan, Jinlan
    Wu, Yafang
    Ceng, Jiannong
    AMERICAN JOURNAL OF HEMATOLOGY, 2007, 82 (06) : 458 - 459
  • [43] Mutation Analysis of Calreticulin in JAK2 V617F-Negative Myeloproliferative Disorders
    Gao, L.
    Stence, A. A.
    Rysgaard, C. D.
    Holman, C. J.
    Bossier, A. D.
    Ma, D.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2014, 16 (06): : 721 - 721
  • [44] Cardiac JAK2 mutation V617F in a patient with cardiomyopathy and myeloproliferative disease
    Gattenlohner, Stefan
    Ertl, Georg
    Einsele, Hermann
    Kircher, Stefan
    Muller-Hermelink, Hans-Konrad
    Marx, Alexander
    ANNALS OF INTERNAL MEDICINE, 2008, 149 (01) : 69 - 71
  • [45] Characterization of murine JAK2V617F-positive myeloproliferative disease
    Bumm, Thomas G. P.
    Elsea, Collin
    Corbin, Amie S.
    Loriaux, Marc
    Sherbenou, Daniel
    Wood, Lisa
    Deininger, Jutta
    Silver, Richard T.
    Druker, Brian J.
    Deininger, Michael W. N.
    CANCER RESEARCH, 2006, 66 (23) : 11156 - 11165
  • [46] Presence of JAK2 V617F mutation in myeloproliferative and myelodysplastic syndrome patients
    Duarte, F.
    Santos, T.
    Barbosa, M.
    Santos, T.
    Goncalves, R.
    LEUKEMIA RESEARCH, 2013, 37 : S99 - S100
  • [47] Concomitant BCR ABL Translocation and JAK2 V617F Mutation in Myeloproliferative Disorders
    Hummel, J. M.
    Sanks, J.
    Chiselite, M.
    Smith, L. B.
    Johnson, K. Elenitoba
    Lim, M. S.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2010, 12 (06): : 869 - 869
  • [48] A microelectronic DNA chip detects the V617F JAK-2 mutation in myeloproliferative disorders
    M Di Ianni
    L Moretti
    B Del Papa
    E Gaozza
    A S Bell
    F Falzetti
    A Tabilio
    Leukemia, 2006, 20 : 1895 - 1897
  • [49] A microelectronic DNA chip detects the V617F JAK-2 mutation in myeloproliferative disorders
    Di Ianni, M.
    Moretti, L.
    Del Papa, B.
    Gaozza, E.
    Bell, A. S.
    Falzetti, F.
    Tabilio, A.
    LEUKEMIA, 2006, 20 (10) : 1895 - 1897
  • [50] AT9283, a potent inhibitor of JAK2, is active in JAK2 V617F myeloproliferative disease models
    Squires, Matthew S.
    Cuny, Jayne E.
    Dawson, Mark A.
    Scott, Mike A.
    Barber, Kelly
    Reule, Matthias
    Smyth, Tomoko
    Wallis, Nicola
    Yule, Murray
    Thompson, Neil T.
    Lyons, John F.
    Green, Anthony K.
    BLOOD, 2007, 110 (11) : 1035A - 1035A
12345